Therapeutic angiogenesis for coronary artery disease

Clinical trials of proteins, plasmids, adenovirus and stem cells

Keith A Webster

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Therapeutic angiogenesis represents a molecular and cellular approach to the treatment of CAD that may be an alternative or additive to traditional pharmacology and interventional cardiology. The goal of angiogenic therapy is to activate endogenous angiogenic and arteriogenic pathways and stimulate revascularization of ischemic myocardial tissue. The feasibility of such a strategy has now been established through the results of studies over the past two decades, and clinical trials involving more than 1000 patients have been implemented. In this review we will discuss the results from these trials, tracing the progression of the technology from the delivery of recombinant proteins through gene and stem cell therapies. Critical evaluations reveal that neither proteins nor genes delivered by transient expression vectors provide an optimal therapy. Similarly, stem cell therapy is not achieving the level of improvement that was expected or predicted from preclinical results. The future of therapeutic angiogenesis lies in the use of permanent gene delivery vehicles expressing regulated genes and/or stem cells appropriately engineered with regulated genes.

Original languageEnglish
Title of host publicationStem Cell and Regenerative Medicine
PublisherBentham Science Publishers Ltd.
Pages65-74
Number of pages10
ISBN (Print)9781608056972
DOIs
StatePublished - Dec 1 2010

Fingerprint

Adenoviridae
Coronary Artery Disease
Plasmids
Stem Cells
Clinical Trials
Cell- and Tissue-Based Therapy
Proteins
Genes
Therapeutics
Myocardial Revascularization
Cardiology
Recombinant Proteins
Pharmacology
Technology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic angiogenesis for coronary artery disease : Clinical trials of proteins, plasmids, adenovirus and stem cells. / Webster, Keith A.

Stem Cell and Regenerative Medicine. Bentham Science Publishers Ltd., 2010. p. 65-74.

Research output: Chapter in Book/Report/Conference proceedingChapter

Webster, Keith A. / Therapeutic angiogenesis for coronary artery disease : Clinical trials of proteins, plasmids, adenovirus and stem cells. Stem Cell and Regenerative Medicine. Bentham Science Publishers Ltd., 2010. pp. 65-74
@inbook{208a5c21359d4f1c91e5ea85b23000ca,
title = "Therapeutic angiogenesis for coronary artery disease: Clinical trials of proteins, plasmids, adenovirus and stem cells",
abstract = "Therapeutic angiogenesis represents a molecular and cellular approach to the treatment of CAD that may be an alternative or additive to traditional pharmacology and interventional cardiology. The goal of angiogenic therapy is to activate endogenous angiogenic and arteriogenic pathways and stimulate revascularization of ischemic myocardial tissue. The feasibility of such a strategy has now been established through the results of studies over the past two decades, and clinical trials involving more than 1000 patients have been implemented. In this review we will discuss the results from these trials, tracing the progression of the technology from the delivery of recombinant proteins through gene and stem cell therapies. Critical evaluations reveal that neither proteins nor genes delivered by transient expression vectors provide an optimal therapy. Similarly, stem cell therapy is not achieving the level of improvement that was expected or predicted from preclinical results. The future of therapeutic angiogenesis lies in the use of permanent gene delivery vehicles expressing regulated genes and/or stem cells appropriately engineered with regulated genes.",
author = "Webster, {Keith A}",
year = "2010",
month = "12",
day = "1",
doi = "10.2174/978160805008611001010065",
language = "English",
isbn = "9781608056972",
pages = "65--74",
booktitle = "Stem Cell and Regenerative Medicine",
publisher = "Bentham Science Publishers Ltd.",

}

TY - CHAP

T1 - Therapeutic angiogenesis for coronary artery disease

T2 - Clinical trials of proteins, plasmids, adenovirus and stem cells

AU - Webster, Keith A

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Therapeutic angiogenesis represents a molecular and cellular approach to the treatment of CAD that may be an alternative or additive to traditional pharmacology and interventional cardiology. The goal of angiogenic therapy is to activate endogenous angiogenic and arteriogenic pathways and stimulate revascularization of ischemic myocardial tissue. The feasibility of such a strategy has now been established through the results of studies over the past two decades, and clinical trials involving more than 1000 patients have been implemented. In this review we will discuss the results from these trials, tracing the progression of the technology from the delivery of recombinant proteins through gene and stem cell therapies. Critical evaluations reveal that neither proteins nor genes delivered by transient expression vectors provide an optimal therapy. Similarly, stem cell therapy is not achieving the level of improvement that was expected or predicted from preclinical results. The future of therapeutic angiogenesis lies in the use of permanent gene delivery vehicles expressing regulated genes and/or stem cells appropriately engineered with regulated genes.

AB - Therapeutic angiogenesis represents a molecular and cellular approach to the treatment of CAD that may be an alternative or additive to traditional pharmacology and interventional cardiology. The goal of angiogenic therapy is to activate endogenous angiogenic and arteriogenic pathways and stimulate revascularization of ischemic myocardial tissue. The feasibility of such a strategy has now been established through the results of studies over the past two decades, and clinical trials involving more than 1000 patients have been implemented. In this review we will discuss the results from these trials, tracing the progression of the technology from the delivery of recombinant proteins through gene and stem cell therapies. Critical evaluations reveal that neither proteins nor genes delivered by transient expression vectors provide an optimal therapy. Similarly, stem cell therapy is not achieving the level of improvement that was expected or predicted from preclinical results. The future of therapeutic angiogenesis lies in the use of permanent gene delivery vehicles expressing regulated genes and/or stem cells appropriately engineered with regulated genes.

UR - http://www.scopus.com/inward/record.url?scp=84882666133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882666133&partnerID=8YFLogxK

U2 - 10.2174/978160805008611001010065

DO - 10.2174/978160805008611001010065

M3 - Chapter

SN - 9781608056972

SP - 65

EP - 74

BT - Stem Cell and Regenerative Medicine

PB - Bentham Science Publishers Ltd.

ER -